Unravelling the antibacterial performances of a homochiral d-configured tetraphenylalanine appended 16-HPA derivative based mechanoresponsive and proteolytically stable hydrogel

揭示基于同手性d-构型四苯丙氨酸修饰的16-HPA衍生物的机械响应性和蛋白水解稳定性水凝胶的抗菌性能

阅读:1

Abstract

Microbial infection is one of the most pressing global challenges worldwide, and imposes significant economic burdens on healthcare systems. This work represents a rational combinatorial strategy that leverages hydrophobic harmony in multiple phenylalanine fragments, anchored to an amphiphile 16-hydroxy-palmitic acid at the N-terminus (16-HPA-d-Phe-d-Phe-OH, compound I; 16-HPA-d-Phe-d-Phe-d-Phe-OH, compound II; 16-HPA-d-Phe-d-Phe-d-Phe-d-Phe-OH, compound III), such that a viable therapeutic skeleton could be uncovered through this strategy. In pursuit of this objective, the minimum inhibitory concentrations of compounds I-III were investigated using four distinct microorganisms namely Staphylococcus aureus and B. subtilis (Gram positive), and E. coli and P. aeruginosa (Gram negative). Our systematic examination reflected that from a pool of three skeletons, compound III comprising of d-configured tetraphenylalanines displayed not only mechanoresponsive assisted hydrogelation propensities at physiological pH, but also excellent antibacterial activities in vitro, in the Gram positive micro-organisms backed by molecular modelling studies. Henceforth compound III was selected from the design and proceeded for its elaborate antibacterial activities using colony counting experiment, bacterial scanning electron microscopy and live-dead assay using flow cytometry. Furthermore, the β-sheet structured compound III, stabilized by weak non-covalent interactions, depicted optimum mechanical strength as well as proteolytic stability for 72 h when exposed to the proteolytic enzyme, proteinase K and chymotrypsin. Overall, our analysis highlights the potential of compound III as a promising candidate for future antimicrobial therapy. However, further experiments are necessary to validate these findings, and current claims are reflective of an early proof-of-concept until further preclinical data are available.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。